Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

17.65USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$17.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
256,922
52-wk High
$20.00
52-wk Low
$8.68

Chart for

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: 2.55
Market Cap(Mil.): $1,197.55
Shares Outstanding(Mil.): 67.85
Dividend: --
Yield (%): --

Financials

  ALDR.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -4.94 -- --
ROI: -63.94 -5.87 13.17
ROE: -103.74 -7.71 15.15

BRIEF-Alder Biopharmaceuticals Reports Q1 Loss Per Share Of $1.73

* ALDER BIOPHARMACEUTICALS® REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

May 08 2018

BRIEF-Alder Biopharmaceuticals Appoints Jeremy Green To Its Board Of Directors

* ALDER BIOPHARMACEUTICALS APPOINTS JEREMY GREEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 26 2018

BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine

* ALDER BIOPHARMACEUTICALS® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE

Apr 25 2018

BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial

* ALDER BIOPHARMACEUTICALS® PRESENTS NEW 12-MONTH DATA OF EPTINEZUMAB IN PROMISE 1 PHASE 3 TRIAL SHOWING LONG-TERM REDUCTION IN EPISODIC MIGRAINE

Apr 24 2018

BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab

* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:

Apr 18 2018

BRIEF-Alder Biopharmaceuticals Appoints Erin Lavelle To Newly Created Role Of Chief Operating Officer

* ALDER BIOPHARMACEUTICALS® APPOINTS ERIN LAVELLE TO NEWLY CREATED ROLE OF CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

Apr 16 2018

BRIEF-Redmile Group Reports 9.99 Pct Stake In Alder Biopharmaceuticals

* REDMILE GROUP, LLC REPORTS 9.99 PERCENT STAKE IN ALDER BIOPHARMACEUTICALS INC AS OF MARCH 23, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2HZWQqw)

Mar 23 2018

BRIEF-Alder Biopharma Q4 Loss Per Share $0.80

* ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

Feb 26 2018

BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva

* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY

Jan 08 2018

BRIEF-Alder Announces $250 Million Committed Equity Financing

* ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT

Jan 08 2018

Competitors

Earnings vs. Estimates